logo image
search icon
Gene Switch / Molecular Switch Market

Gene Switch / Molecular Switch Market, Share & Trends Analysis Report, Distribution by Application Area (Management of Treatment Related Toxicity, Regulation of Gene Expression), Type of Target Therapy (CAR T Cell Therapy, Gene Therapy), Type of Payment Model Employed, By Region, and Segment Forecasts, 2024-2031

Report ID : 2595 | Published : 2024-07-22 | Pages: 168 | Format: PDF/EXCEL

The Gene Switch / Molecular Switch Market Size is valued at USD 0.69 Bn in 2023 and is predicted to reach USD 1.44 Bn by the year 2031 at an 9.9% CAGR during the forecast period for 2024-2031.

gene switch

Gene switches are locations on genes that are capable of binding regulatory molecules to start the transcription and translation processes that result in the expression of that particular gene. Gene switching pertains to the reversible on/off regulation of gene expression or the regulation of gene expression between two alleles. Any gene's ability to be expressed is based on how quickly it is translated from mRNA into proteins and back again. The transcription rate is influenced by specific transcription factors, also known as regulatory proteins. Regulatory proteins or particular DNA sequences can function as gene switches, turning on or off a gene's expression.

Gene switches also referred to as molecular switches, genetic switches, safety switches, or suicide switches are crucial parts of genetic circuits with a variety of uses in developmental biology, synthetic biology, and gene therapy. Gene switch systems with reversible ON/OFF safety switches are commonly used to improve the safety of modified T-cell treatments. Numerous investigations are currently being conducted to assess safety switches based on small molecules for diverse cell-based therapies. Gene switches are also used to extend the lifespan of activated cell therapies and control the expression of transgenes in a variety of gene therapies without the need for extra protein components. These applications result in long-lasting patient responses to therapeutics by promoting effector cell proliferation and lifespan extension.

The market for gene switches is expanding quickly due to the growing uses of gene switches in a variety of therapeutic areas as well as rising investments in biotechnology and pharmaceutical research. Additionally, the creation of medical devices based on gene switches has the potential to completely transform the way diseases are treated by providing individualized and focused therapies that lead to better patient outcomes. The gene switch market is expected to propel revolutionary developments in medical devices as the field develops, influencing the direction of customized medicine and healthcare delivery in the future.

Competitive Landscape

Some of the Major Key Players in the Gene Switch / Molecular Switch Market are

  • aceRNA Technologies
  • Autolus Therapeutics
  • Bellicum Pharmaceuticals
  • Cellectis
  • Kiromic BioPharma
  • panCELLa
  • Precigen,
  • Sana Biotechnology
  • Sangamo Therapeutics
  • Editas Medicine
  • Other Prominent Players

Market Segmentation:

The is segmented based on by application area, by offering, type of target therapy, type of payment model employed, by region. By application area segmented into management of treatment related toxicity, regulation of gene expression and other applications. Based on the type of target therapy, the market is categorized into CAR T cell therapy, gene therapy and other therapies. Based on the type of payment model employed, the market divided into upfront payments and milestone payments.

The Regulation of Gene Expression Segment is Expected to have the highest growth rate during the forecast period

Based on the by application area, the market is categorized into management of treatment related toxicity, regulation of gene expression and other applications. Among these, the regulation of gene expression segment is expected to have the highest growth rate during the forecast period. Regulation of gene expression allows for precise control over therapeutic genes, enabling targeted treatments with reduced off-target effects. The rapid development of gene editing technologies like CRISPR/Cas9 has revolutionized the field, making it easier to develop gene switches that can regulate gene expression with high specificity and efficiency.

The CAR T Cell Therapy Segment Dominate the Market

Based on the type of target therapy, the market is categorized into CAR T cell therapy, gene therapy and other therapies. CAR T cell therapies have shown significant success in treating certain types of cancers, especially hematologic malignancies like leukemia and lymphoma. The ability to reprogram T cells to specifically target and destroy cancer cells has proven highly effective. The field of CAR T cell therapy attracts substantial investments from pharmaceutical companies, biotech firms, and research institutions. These investments are directed towards improving the efficacy, safety, and scalability of CAR T cell therapies.

North America to Hold the Largest Gene Switch Market During The Forecast Period.

North America has the largest market share due to there is substantial investment in research and development from both public and private sectors. The National Institutes of Health (NIH) and numerous private foundations and venture capital firms provide significant funding for cutting-edge research in gene therapy and gene switches. North America has seen several landmark approvals of gene therapies and CAR T cell therapies, which have paved the way for increased investment and interest in this field.

Recent Developments:

  • In Feb, 2024, The University of Texas MD Anderson Cancer Center, declared that it has purchased a number of assets from Bellicum Pharmaceuticals, Inc. pertaining to the GoCAR® and CaspaCIDe® switch platforms. Clinical-grade supplies of rimiducid, the chemical that activates the switches, are also included in the transaction. MD Anderson may use these platforms in its own cell therapy programs as a result of this acquisition. Additionally, the school plans to grant non-exclusive licenses to biopharmaceutical businesses and other academic institutions, thereby making the technology publicly accessible.
  • In April 2024, Cellectis, declared the release of a new study in Molecular Therapy, which shows that transgene expression limited to the myeloid lineage can be achieved using TALEN-mediated intron editing of hematopoietic stem and progenitor cells (HSPCs). This strategy may open up new therapeutic options for the treatment of neurological conditions that call for the transport of medications to the brain, as well as inborn metabolic illnesses. 

Gene Switch / Molecular Switch Market Report Scope

Report Attribute

Specifications

Market Size Value In 2023

USD 0.69 Bn

Revenue Forecast In 2031

USD 1.44 Bn

Growth Rate CAGR

CAGR of 9.9% from 2024 to 2031

Quantitative Units

Representation of revenue in US$ Bn and CAGR from 2024 to 2031

Historic Year

2019 to 2023

Forecast Year

2024-2031

Report Coverage

The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends

Segments Covered

by Application Area, Type of Target Therapy, Type of Payment Model Employed

Regional Scope

North America; Europe; Asia Pacific; Latin America; Middle East & Africa

Country Scope

U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; Southeast Asia; South Korea; South East Asia

Competitive Landscape

aceRNA Technologies, Autolus Therapeutics, Bellicum Pharmaceuticals, Cellectis, Kiromic, BioPharma, panCELLa, Precigen, Sana Biotechnology, Sangamo Therapeutics, Editas Medicine

Customization Scope

Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape.

Pricing and Available Payment Methods

Explore pricing alternatives that are customized to your particular study requirements.

Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global Gene Switch / Molecular Switch Market Snapshot

Chapter 4. Global Gene Switch / Molecular Switch Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis

Chapter 5. Market Segmentation 1: Type of Payment Model Employed Area Estimates & Trend Analysis
5.1. Type of Payment Model Employed Area & Market Share, 2019 & 2031
5.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following Type of Payment Model Employed Area:

5.2.1. Management of Treatment Related Toxicity
5.2.2. Regulation of Gene Expression
5.2.3. Other Applications

Chapter 6. Market Segmentation 2: Type of Target Therapy Estimates & Trend Analysis
6.1. Type of Target Therapy & Market Share, 2019 & 2031
6.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following Type of Target Therapy:

6.2.1. CAR T Cell Therapy
6.2.2. Gene Therapy
6.2.3. Other Therapies

Chapter 7. Market Segmentation 3: Type of Payment Model Employed Estimates & Trend Analysis
7.1. Type of Payment Model Employed & Market Share, 2019 & 2031
7.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following Type of Payment Model Employed:

7.2.1. Upfront Payments
7.2.2. Milestone Payments

Chapter 8. Gene Switch / Molecular Switch Market Segmentation 4: Regional Estimates & Trend Analysis

8.1. North America
8.1.1. North America Gene Switch / Molecular Switch Market Revenue (US$ Million) Estimates and Forecasts Type of Payment Model Employed Area, 2024-2031
8.1.2. North America Gene Switch / Molecular Switch Market Revenue (US$ Million) Estimates and Forecasts Type of Target Therapy, 2024-2031
8.1.3. North America Gene Switch / Molecular Switch Market Revenue (US$ Million) Estimates and Forecasts Type of Payment Model Employed, 2024-2031
8.1.4. North America Gene Switch / Molecular Switch Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031

8.2. Europe
8.2.1. Europe Gene Switch / Molecular Switch Market Revenue (US$ Million) Estimates and Forecasts Type of Payment Model Employed Area, 2024-2031
8.2.2. Europe Gene Switch / Molecular Switch Market Revenue (US$ Million) Estimates and Forecasts Type of Target Therapy, 2024-2031
8.2.3. Europe Gene Switch / Molecular Switch Market Revenue (US$ Million) Estimates and Forecasts Type of Payment Model Employed, 2024-2031
8.2.4. Europe Gene Switch / Molecular Switch Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031

8.3. Asia Pacific
8.3.1. Asia Pacific Gene Switch / Molecular Switch Market Revenue (US$ Million) Estimates and Forecasts Type of Payment Model Employed Area, 2024-2031
8.3.2. Asia Pacific Gene Switch / Molecular Switch Market Revenue (US$ Million) Estimates and Forecasts Type of Target Therapy, 2024-2031
8.3.3. Asia-Pacific Gene Switch / Molecular Switch Market Revenue (US$ Million) Estimates and Forecasts Type of Payment Model Employed, 2024-2031
8.3.4. Asia Pacific Gene Switch / Molecular Switch Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031

8.4. Latin America
8.4.1. Latin America Gene Switch / Molecular Switch Market Revenue (US$ Million) Estimates and Forecasts Type of Payment Model Employed Area, 2024-2031
8.4.2. Latin America Gene Switch / Molecular Switch Market Revenue (US$ Million) Estimates and Forecasts Type of Target Therapy, 2024-2031
8.4.3. Latin America Gene Switch / Molecular Switch Market Revenue (US$ Million) Estimates and Forecasts Type of Payment Model Employed, 2024-2031
8.4.4. Latin America Gene Switch / Molecular Switch Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031

8.5. Middle East & Africa
8.5.1. Middle East & Africa Gene Switch / Molecular Switch Market Revenue (US$ Million) Estimates and Forecasts Type of Payment Model Employed Area, 2024-2031
8.5.2. Middle East & Africa Gene Switch / Molecular Switch Market Revenue (US$ Million) Estimates and Forecasts Type of Target Therapy, 2024-2031
8.5.3. Middle East & Africa Gene Switch / Molecular Switch Market Revenue (US$ Million) Estimates and Forecasts Type of Payment Model Employed, 2024-2031
8.5.4. Middle East & Africa Gene Switch / Molecular Switch Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031

Chapter 9. Competitive Landscape
9.1. Major Mergers and Acquisitions/Strategic Alliances
9.2. Company Profiles

9.2.1. aceRNA Technologies
9.2.2. Autolus Therapeutics
9.2.3. Bellicum Pharmaceuticals
9.2.4. Cellectis
9.2.5. Kiromic BioPharma
9.2.6. panCELLa
9.2.7. Precigen,
9.2.8. Sana Biotechnology
9.2.9. Sangamo Therapeutics
9.2.10. Editas Medicine
9.2.11. Other Prominent Players

Segmentation of Gene Switch / Molecular Switch Market

Global Gene Switch / Molecular Switch Market, by Application Area

  • Management of Treatment Related Toxicity
  • Regulation of Gene Expression
  • Other Application

gene switch

Global Gene Switch / Molecular Switch Market – Type of Target Therapy

  • CAR T Cell Therapy
  • Gene Therapy
  • Other Therapies

Global Gene Switch / Molecular Switch Market – Type of Payment Model Employed

  • Upfront Payments
  • Milestone Payments

Global Gene Switch / Molecular Switch Market – By Region

North America-

  • The US
  • Canada
  • Mexico

Europe-

  • Germany
  • The UK
  • France
  • Italy
  • Spain
  • Rest of Europe

Asia-Pacific-

  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific

Latin America-

  • Brazil
  • Argentina
  • Rest of Latin America

 Middle East & Africa-

  • GCC Countries
  • South Africa
  • Rest of the Middle East and Africa

InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.

Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.

Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.

Secondary research

The secondary research sources that are typically mentioned to include, but are not limited to:

  • Company websites, financial reports, annual reports, investor presentations, broker reports, and SEC filings.
  • External and internal proprietary databases, regulatory databases, and relevant patent analysis
  • Statistical databases, National government documents, and market reports
  • Press releases, news articles, and webcasts specific to the companies operating in the market

The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista

Primary Research:

Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies

The contributors who typically take part in such a course include, but are not limited to: 

  • Industry participants: CEOs, CBO, CMO, VPs, marketing/ type managers, corporate strategy managers, and national sales managers, technical personnel, purchasing managers, resellers, and distributors.
  • Outside experts: Valuation experts, Investment bankers, research analysts specializing in specific markets
  • Key opinion leaders (KOLs) specializing in unique areas corresponding to various industry verticals
  • End-users: Vary mainly depending upon the market

Data Modeling and Analysis:

In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.

The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.

To know more about the research methodology used for this study, kindly contact us/click here.

user icon
office icon
mail icon
call icon

This website is secure, and we do not share your personal information with any third party. Privacy Policy

Need Customization
Need specific information/chapter from the report of the custom data table, graph or complete report? Tell us more.

Frequently Asked Questions

How big is the Gene Switch / Molecular Switch Market Size?

The Gene Switch / Molecular Switch Market is predicted to grow at a 9.9% CAGR during the forecast period for 2024-2031.

aceRNA Technologies, Autolus Therapeutics, Bellicum Pharmaceuticals, Cellectis, Kiromic, BioPharma, panCELLa, Precigen, Sana Biotechnology, Sangamo Th

Our Clients

  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo

Media Citations

  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo

Growth opportunities and latent adjacency in Pharmaceuticals

Select Licence Type
$4456
$7786
$10000
$1200
Get Your GTM Strategy

Navigate market entry with channel selection, launch strategy & timeline, and pricing model support.

Equip yourself with the insights needed to develop a winning go-to-market strategy

Get real-time updates and joint control over project direction with our collaborative approach